JP Morgan maintains Zimmer Biomet Holdings at Neutral, raises price target to $120 from $117

JP Morgan kept its Neutral rating on Zimmer Biomet Holdings but raised its price target to $120 from $117, suggesting a 12.3% upside from the Nov 5 close of $106.85. Recent analyst price targets for the company range from $107 to $125.

Original reporting
Published Nov 5, 2026, 11:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 11:54 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
JP Morgan maintains Zimmer Biomet Holdings at Neutral, raises price target to $120 from $117 — source image
Decision brief

The 30-second read

$ZBHBullishMed
01

Why it matters

The upgrade may generate modest buying pressure, but the small magnitude limits its trading significance.

02

Market read

A minor analyst upgrade that could produce limited upside for ZBH.

03

What to watch

Potential supply-chain constraints or upcoming earnings could outweigh the small analyst upgrade.

Relevance 6/10Novelty 5/10Timing: today

Background

JP Morgan's analyst note updates the price target for Zimmer Biomet Holdings, reflecting a slight improvement in its valuation outlook.

Company-level read

Ticker impact

$ZBHBullishMedium confidence
Context

JP Morgan raised its price target on Zimmer Biomet Holdings to $120 from $117, indicating a fresh analyst upgrade.

Expected impact

potential modest upside as the market prices in the higher target

Evidence & confidence

The new target is only 2.6% higher and reflects a slight improvement in outlook, likely prompting limited buying interest.

Market effects

May slightly lift the orthopedics/medical devices sector as analysts adjust expectations.

Limited to U.S. equities; no broader regional effect.

Minimal global impact; primarily relevant to investors in ZBH.

Counterpoint

The modest target raise may be insufficient to justify a position given broader market volatility.

Key entities

  • Zimmer Biomet Holdings

    Medical device manufacturer whose price target was raised.

  • JP Morgan

    Issued the new price target.

Related articles

$ZBHMed

What Zimmer Biomet (ZBH) Said on Its Q3 Earnings Call

Zimmer Biomet (ZBH) reported Q3 sales growth of 13% in technology, bone cement, and surgical sales, but a 2.6% decline in global knee sales. CEO Tornos attributed knee underperformance to commercial execution. The company expects to launch its Monogram robotic system in early 2027. Q3 adjusted earnings were $1.90 per share, with margins declining but cash flow rising. Full-year sales growth guidance was raised to 4.4%-4.9%.

$ZBHMed

Truist raises Zimmer Biomet stock price target on robotics progress

Truist Securities raised Zimmer Biomet's (ZBH) price target to $114 from $106, citing 3.7% Q3 organic revenue growth, though EPS missed estimates. The stock is up 13% in a week. Analysts note progress in robotics and hip segments, but caution on knee division weakness and future risks. Other analysts also raised targets, with Stifel at $125 and Jefferies at $120.

$ZBHMed

Zimmer Biomet Holdings Inc (ZBH) (Q3 2026) Earnings Call Highlights: Guidance Raised as Hips

Zimmer Biomet (ZBH) reported Q3 2026 earnings, raising guidance despite a 2.6% decline in knee business due to sales force transition and competitive pressure. Adjusted operating margin fell 140 basis points to 25.1%, and gross margin decreased 90 basis points to 71.7%. CEO Ivan Tornos highlighted sustainable growth in hips and S.E.T. areas, but acknowledged underperformance in knees. China headwinds and sales force disruption pose risks.